The Best from the 47th Annual Meeting of the European Association for the Study of Diabetes, Lisbon, Portugal. See all of our coverage on the 47th EASD from the details on the latest diabetes figures worldwide to the potential of a new Once-A-Year diabetes medication.

 A National Randomized Trial Lisa M. Schwartz, MD, MS; Steven Woloshin, MD, MS Background Many new drugs are aggressively promoted. The public may not realize that even with US Food and Drug Administration (FDA) approval, important uncertainties about the benefits and harms of these drugs remain. We assessed the US …

Once-A-Year Non-Injectable Byetta The DUROS delivery system aims to reshape the way diabetes is treated by offering patients and their health care providers with a more convenient long term treatment regiment. The result is the investigational treatment now in late stage development — ITCA 650. As part of a robust …

Americans are well informed about the risks, dangers, and signs of diabetes — but that knowledge does not appear to translate into actions to prevent or control the disease, researchers reported. Almost 87% of the 3,867 type 2 diabetes respondents in a huge national sampling knew that obesity contributes to …

Survival rates in patients with early-onset type 1 diabetes have improved in recent years, whereas survival in patients with late-onset type 1 diabetes has become worse since the 1980s. The trend appears to be a result of increases in drug- and alcohol-related deaths in patients with late-onset type 1 diabetes. …

Walking more not only wards off weight gain in middle age but also helps prevent or delay diabetes, a population-based study affirmed. Middle-age people who increased their daily step count over five years maintained significantly higher insulin sensitivity at the end of that period than those who didn’t boost their …

According to the latest figures from the International Diabetes Federation (IDF), released in advance of a UN summit on non-communicable diseases, 366 million people worldwide now have diabetes.…

Intensive glucose-lowering may protect against end-stage renal disease (ESRD) in diabetic patients, according to an analysis of data from the ADVANCE trial….

ITCA 650, injection-free continuous delivery of GLP-1 therapy, demonstrated significant and sustained reductions in HbA1c and body weight over 48 weeks of treatment with a marked reduction in the GI AEs typically associated with this class.…

A new nationwide analysis of glucose management in type 2 diabetes suggests that poor glucose control is a strong predictor of heart failure.…